Review of Operations Directors’ Report Chairman’s Letter CEO’s Report Financial Report Shareholder Information Dr Hinch (appointed 7 November 2016) Dr Leearne Hinch has an Executive Employment Agreement with the Company dated 7 November 2016 to perform the role of Chief Executive Officer, under which Dr Hinch is paid a total fixed remuneration of $433,568 per annum plus superannuation payable under the Superannuation Guarantee Act (current at 30 June 2025). This arrangement can be terminated by either party by providing 6 months written notice. A Short-Term Incentive (STI) bonus of $90,000 was paid during the financial year for the achievement of agreed key performance indicators (KPIs) for the 12 months to 30 June 2024. This STI was paid in November 2024. Dr Rice (appointed 20 September 2021) Dr Greg Rice has an Employment Agreement with the Company dated 20 September 2021 to perform the role of Chief Scientific Officer of the Group with a total fixed remuneration of $295,964 per annum plus superannuation entitlement (current at 30 June 2025). This remuneration is paid on a pro-rata basis to reflect Dr Rice shifting to part time employment during the current year. This arrangement can be terminated by either party providing 3 months written notice. A Short-Term Incentive (STI) bonus of $27,803 (plus superannuation) was paid during the financial year for the achievement of agreed key performance indicators (KPIs) for the 30 June 2024 year. This STI was paid in November 2024. Mr Edwards (appointed 2 November 2022) Mr Mark Edwards has an Employment Agreement with the Group dated 21 September 2022 to perform the role of Chief Financial Officer and Company Secretary with a total fixed remuneration of $275,068 plus superannuation entitlement (current at 30 June 2025). The arrangement can be terminated by either party providing 3 months written notice. A Short-Term Incentive (STI) bonus of $29,500 was paid during the financial year for the achievement of agreed key performance indicators (KPIs) for the 30 June 2024 year. This STI was paid in November 2024. At the date of this report the Company does not have any other consultancy or employment agreements in place with KMP. REMUNERATION OF KEY MANAGEMENT PERSONNEL Short Term Benefits Salary & Fees $ Bonus* $ Post - Employment Benefits Superannuation $ Long Term Benefits $ Share Based Payments (Options)# $ Total $ Percentage (%) Fixed Rem. Variable Rem. D Williams1 2025 90,090 – 10,360 – 634,922 735,372 14% 86% Chairman 2024 52,552 – 5,781 – 671,479 729,812 8% 92% G Cumming 2025 60,000 – 6,900 – 19,693 86,593 77% 23% Non-Exec Director 2024 67,500 – 7,425 – – 74,925 100% – P Powell 2025 60,000 – 6,900 – 19,693 86,593 77% 23% Non-Exec Director 2024 56,667 – 6,233 – – 62,900 100% – M Johnston 2025 60,000 – 6,900 – 19,693 86,593 77% 23% Non-Exec Director 2024 56,667 – 6,233 – – 62,900 100% – M Harney2 2025 45,000 – 5,175 – 19,693 69,868 72% 28% Non-Exec Director 2024 – – – – – – – – L Hinch 2025 430,193 90,000 29,93210,372 60,839621,33676%24% CEO 2024 414,365 42,500 27,39911,405 113,642609,311 74% 26% Mark Edwards 2025 272,568 29,500 29,932 5,097 7,077 344,174 89% 11% CFO and Co Sec 2024 262,601 15,000 27,399 1,338 16,535 322,873 90% 10% G Rice 2025 217,063 27,803 28,160 5,843 7,907 286,776 88% 12% CSO 2024 279,268 15,000 27,399 5,431 23,149 350,247 89% 11% Total 2025 1,234,914 147,303 124,259 21,312 789,517 2,317,305 60% 40% Total 2024 1,189,620 72,500 107,869 18,174 824,805 2,212,968 59% 41% 1 D Williams appointed 29 November 2023 2 M Harney appointed 1 October 2024 # The amounts reported represent non-cash expense required to be calculated under accounting standard AASB 2 – Share-based Payments * Bonuses were determined by the Board for the achievement of agreed key performance indicators. The KPI’s achieved include a range of operational initiatives and research and product development milestones. 25 Annual Report 2025
RkJQdWJsaXNoZXIy MjE2NDg3